Companies Connect Biopharma Holdings
Connect Biopharma (CNTB): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Connect Biopharma Holdings’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $4,521,436FY2024
- $2,507,764FY2025
CEO total pay was $2,507,764 in fiscal 2025, down from $4,521,436 in fiscal 2024.
FY2025: salary $660,800 · bonus $0 · stock awards $0 · option awards $1,527,540
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Barry Quart | $660,800 | $0 | $0 | $1,527,540 | $308,924 | $0 | $10,500 | $2,507,764 |
| Chief Executive Officer | ||||||||
| David Szekeres | 508,400 | 0 | 0 | 872,880 | 216,070 | 0 | 10,500 | 1,607,850 |
| President | ||||||||
| Lisa Peraza | 414,620 | 0 | 0 | 583,661 | 146,006 | 0 | 10,500 | 1,154,787 |
| Senior Vice President, Finance | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Barry Quart | $2,507,764 | $4,521,436 | — | ↓ −2,013,672 |
| David Szekeres | 1,607,850 | 3,149,075 | — | ↓ −1,541,225 |
| Lisa Peraza | 1,154,787 | 608,652 | — | ↑ +546,135 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Lisa Peraza | OPTION | 2025-07-07 | — | — | 40,000 | — | — |
| Lisa Peraza | OPTION | 2025-12-26 | — | — | 250,000 | — | — |
| Barry Quart | OPTION | 2025-12-26 | — | — | 700,000 | — | 1,527,540 |
| David Szekeres | OPTION | 2025-12-26 | — | — | 400,000 | — | 872,880 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Barry Quart | $0 | $0 | $1,527,540 | 0.0% |
| David Szekeres | 0 | 0 | 872,880 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Lisa Peraza | Option | 40,000 | 1.14 | — |
| Lisa Peraza | Option | 41,489 | 0.97 | — |
| Lisa Peraza | Option | 250,000 | 2.69 | — |
| Lisa Peraza | Option | 266,667 | 1.15 | — |
| David Szekeres | Option | 307,017 | 0.97 | — |
| Barry Quart | Option | 324,294 | 0.97 | — |
| David Szekeres | Option | 400,000 | 2.69 | — |
| Barry Quart | Option | 700,000 | 2.69 | — |
| David Szekeres | Option | 1,107,806 | 1.77 | — |
| Barry Quart | Option | 1,661,709 | 1.77 | — |
Director compensation
No director compensation table is on file for fiscal year 2025.
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Peer group, and who names Connect Biopharma as a peer
Companies that benchmark against CNTB
No companies currently name CNTB as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Connect Biopharma Holdings | 2025 | Barry Quart | $660,800 | $0 | $1,527,540 | $308,924 | $2,507,764 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (10 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Barry Quart. 10-K, filed 2026-03-31. Section “Executive Compensation” · page 141. As printed: 2,507,764. View filing ↗
- Section 01, David Szekeres. 10-K, filed 2026-03-31. Section “Executive Compensation” · page 141. As printed: 1,607,850. View filing ↗
- Section 01, Lisa Peraza. 10-K, filed 2026-03-31. Section “Executive Compensation” · page 141. As printed: 1,154,787. View filing ↗
- Section 03, Lisa Peraza OPTION. 10-K, filed 2026-03-31. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Lisa Peraza OPTION. 10-K, filed 2026-03-31. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Barry Quart OPTION. 10-K, filed 2026-03-31. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, David Szekeres OPTION. 10-K, filed 2026-03-31. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Connect Biopharma Holdings (subject), Section 10b CEO total. 10-K, filed 2026-03-31. CEO total compensation as printed in Connect Biopharma Holdings's own proxy. As printed: 2,507,764. View filing ↗